• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 13, 2016

View Archived Issues

Hospitals add to clamor over drug price hikes

Jumping on the bandwagon about escalating drug prices, the U.S. hospital industry released a report Tuesday showing how random, unpredictable drug costs are hurting community hospitals. Read More

Akriveia new playa: $7.5M round for immunotherapy next early bid via F-Prime

CEO Simon Tomlinson told BioWorld Today that Akriveia Therapeutics LLC's approach "exploits the differential biochemistry of the tumor micro-environment to activate an otherwise inert biologic molecule in the vicinity of the tumor," a rational-design strategy to "bioengineer the optimal tumor-targeted biologic." Read More

Rxi lays foundation for Mirimmune buy

Rxi Pharmaceuticals Corp. negotiated an exclusive option to acquire privately held cancer immunotherapy developer Mirimmune Inc. The all-stock deal will give Mirimmune shareholders nearly a 20 percent equity stake in Rxi should it close as expected and could provide it further equity-based payments upon hitting certain undisclosed milestones. Read More

Cell-based studies bring toxicity insights

By studying drug mechanisms of actions in living cells, researchers have been able to show that the ocular toxicity of inhibitors of the beta-secretase beta-site APP-cleaving enzyme 1 (BACE1), which are in clinical trials for the treatment of Alzheimer's disease (AD), is due to inhibition of the related enzyme Cathepsin D. More broadly, they wrote in their paper, their results "underscore the power of chemical proteomics for discerning mechanisms of drug action." Read More

Nano-sized radiation enhancers for tumor treatment soon entering the European market

PARIS – Nanobiotix SA has submitted its lead product NBTXR3 – the first generation of nanoparticle radio-enhancers targeting human cells – for first market approval in Europe. This nanotechnology is intended to resolve radiation therapy's biggest drawback: the destruction of healthy tissue and subsequent deleterious side effects when high X-ray doses are necessary. Read More

Financings

GTx Inc., of Memphis, Tenn., said it has entered definitive agreements with certain existing shareholders to sell about 17.3 million shares of its common stock at a purchase price of $0.81 per share to raise approximately $14 million in a registered direct offering. Read More

Other news to note

Amag Pharmaceuticals Inc., of Waltham, Mass., said it achieved two key milestones in its next-generation development programs. Read More

In the clinic

Prometic Life Sciences Inc., of Laval, Quebec, said the drug safety monitoring board recommended that patient enrollment should continue in the company's Alström syndrome phase II trial. This recommendation follows the board's review of the safety data accumulated in the first eight Alström syndrome patients that had received treatment with PBI-4050. Read More

Appointments and advancements

4SC AG, of Planegg-Martinsried, Germany, appointed Jason Loveridge CEO. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe